- Moneycontrol /
- Market /
- Pharmaceuticals /
- YEARLY RESULTS
BSE Live
Jan 22, 16:00Prev. Close
493.05
Open Price
498.80
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Jan 22, 15:59Prev. Close
493.20
Open Price
498.00
Bid Price (Qty.)
497.95 (1307)
Offer Price (Qty.)
0.00 (0)
| Yearly Results of Aurobindo Pharma (in Rs. Cr.) | Mar '19 | Mar '18 | Mar '17 | Mar '16 | Mar '15 | |
| Net Sales/Income from operations | 11,938.70 | 10,041.96 | 9,539.36 | 9,078.96 | 8,018.00 | |
| Other Operating Income | 319.19 | 261.19 | 241.85 | 243.80 | 77.10 | |
| Total Income From Operations | 12,257.89 | 10,303.15 | 9,781.21 | 9,322.76 | 8,095.10 | |
| EXPENDITURE | ||||||
| Consumption of Raw Materials | 6,455.30 | 4,893.27 | 4,604.19 | 4,425.80 | 3,920.33 | |
| Purchase of Traded Goods | 14.25 | 3.72 | 11.21 | 6.31 | 15.76 | |
| Increase/Decrease in Stocks | -289.80 | -334.18 | 31.32 | -141.59 | -159.09 | |
| Power & Fuel | -- | -- | -- | -- | -- | |
| Employees Cost | 1,362.77 | 1,131.64 | 927.30 | 807.05 | 668.75 | |
| Depreciation | 413.03 | 354.83 | 286.17 | 263.00 | 245.15 | |
| Excise Duty | -- | -- | -- | -- | -- | |
| Admin. And Selling Expenses | -- | -- | -- | -- | -- | |
| R & D Expenses | -- | -- | -- | -- | -- | |
| Provisions And Contingencies | -- | -- | -- | -- | -- | |
| Exp. Capitalised | -- | -- | -- | -- | -- | |
| Other Expenses | 2,316.40 | 1,938.69 | 1,833.24 | 1,937.45 | 1,398.93 | |
| P/L Before Other Inc. , Int., Excpt. Items & Tax | 1,985.94 | 2,315.18 | 2,087.78 | 2,024.74 | 2,005.27 | |
| Other Income | 109.60 | 80.65 | 135.95 | 188.37 | 42.32 | |
| P/L Before Int., Excpt. Items & Tax | 2,095.54 | 2,395.83 | 2,223.73 | 2,213.11 | 2,047.59 | |
| Interest | 130.92 | 52.89 | 45.16 | 65.27 | 107.25 | |
| P/L Before Exceptional Items & Tax | 1,964.62 | 2,342.94 | 2,178.57 | 2,147.84 | 1,940.34 | |
| Exceptional Items | -- | -- | -- | -- | -- | |
| P/L Before Tax | 1,964.62 | 2,342.94 | 2,178.57 | 2,147.84 | 1,940.34 | |
| Tax | 434.89 | 530.17 | 471.81 | 521.14 | 424.00 | |
| P/L After Tax from Ordinary Activities | 1,529.73 | 1,812.77 | 1,706.76 | 1,626.70 | 1,516.34 | |
| Prior Year Adjustments | -- | -- | -- | -- | -- | |
| Extra Ordinary Items | -- | -- | -- | -- | -- | |
| Net Profit/(Loss) For the Period | 1,529.73 | 1,812.77 | 1,706.76 | 1,626.70 | 1,516.34 | |
| Equity Share Capital | 58.59 | 58.59 | 58.59 | 58.52 | 29.20 | |
| Reserves Excluding Revaluation Reserves | 11,292.03 | 9,923.99 | 8,377.59 | 6,807.33 | 5,330.34 | |
| Equity Dividend Rate (%) | 250.00 | 250.00 | 250.00 | 250.00 | 300.00 | |
| EPS Before Extra Ordinary | ||||||
| Basic EPS | 26.11 | 30.94 | 29.16 | 27.85 | 52.01 | |
| Diluted EPS | 26.11 | 30.94 | 29.16 | 27.84 | 51.97 | |
| EPS After Extra Ordinary | ||||||
| Basic EPS. | 26.11 | 30.94 | 29.16 | 27.85 | 52.01 | |
| Diluted EPS. | 26.11 | 30.94 | 29.16 | 27.84 | 51.97 | |
| Public Share Holding | ||||||
| No Of Shares (Crores) | -- | -- | -- | -- | 13.44 | |
| Share Holding (%) | -- | -- | -- | -- | 46.03 | |
| Promoters and Promoter Group Shareholding | ||||||
| a) Pledged/Encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | 1.00 | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | 6.35 | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | 3.43 | |
| b) Non-encumbered | ||||||
| - Number of shares (Crores). | -- | -- | -- | -- | 14.76 | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group). | -- | -- | -- | -- | 93.65 | |
| - Per. of shares (as a % of the total Share Cap. of the company). | -- | -- | -- | -- | 50.54 |
16.11.2019
Earnings hits & misses: Top 10 companies which declared Q2 numbers this week
13.11.2019
Aurobindo Pharm Consolidated September 2019 Net Sales at Rs 5,600.47 crore, up 17.87% Y-o-Y
12.11.2019
10.08.2019
Surprise or disappointment in Q1: Here's how top companies have performed last week
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL
